Cogstate has been chosen by the Global Alzheimer’s Platform (GAP) Foundation to support GAP’s rater certification program (RCP) that will increase the speed and quality of Alzheimer’s clinical trials. The RCP is designed to qualify and train clinical trial site personnel to administer cognitive and functional assessments required for Alzheimer’s disease (AD) studies.
“GAP’s mission is to accelerate the development of new treatments for Alzheimer’s disease. We hope to eliminate redundant rater training – thereby providing a faster pathway for AD clinical trial sites to start enrolling their trials,” Jason Bork, Chief Operating Officer, Global Alzheimer’s Platform Foundation said. “Our partnership with Cogstate and our unprecedented rater certification program will speed the study start for AD trials and reduce trial completion delays due to rater turnover.”